The second cohort of the Ready2Scale Acceleration Program is well underway, supporting ambitious deep-tech startups from across Europe with tailored mentorship, resources, and €60,000 grants. One of the standout participants is Biomedical Lab, the company behind the PD-Watch – an innovative solution aimed at improving care for people with Parkinson’s disease.
Biomedical Lab is the developer of PD-Watch, a software application designed to work with professional wearables and smartwatches. It supports the diagnosis of Parkinsonian motor syndromes and enables continuous monitoring of Parkinson’s motor signs. The system collects sensor data from wearable devices and applies patented algorithms and processing methods to detect subtle motor changes—helping identify early signs of Parkinson’s disease. For individuals already diagnosed, PD-Watch offers continuous tracking that assists doctors in optimizing treatment plans and improving patient outcomes.
The company was founded by Dr. Noemi Giorgio, CEO, who holds a degree in Science of Education and a Master’s in Psychology, and Eng. Luigi Battista, Ph.D., the inventor of PD-Watch with over 15 years of experience in biomedical engineering.
How did the idea for your startup originate?
Luigi, with a background in biomedical engineering, was conducting a study on accelerometers and envisioned an application in the field of Parkinson’s disease. After engaging with patients and doctors, the team moved forward with developing what is now the PD-Watch.
What have been your biggest challenges and most significant achievements so far?
We have faced several challenges, but through dedication and sacrifice, we succeeded in developing a patented solution that has undergone clinical testing. It is currently in use in healthcare facilities both in Italy and abroad and is now ready for a new, innovative release.
What drives you to continue, even during difficult times?
What drives us is the belief that our work can improve the lives of many—people with Parkinson’s and their caregivers—and eventually help in early detection of the disease. This conviction keeps us moving forward.
What sets your startup apart from competitors?
The PD-Watch stands out due to its ability to not only monitor Parkinson’s patients continuously but also distinguish between normal motor activity and pathological movements caused by neurodegenerative conditions. Its patented processing method is a key differentiator. Unlike many wearable systems that focus only on monitoring, PD-Watch also provides diagnostic capabilities, reaching a validated diagnostic accuracy of 84%.
What are your expectations from the Ready2Scale Acceleration Programme, and how do you think it will benefit your startup?
We see Ready2Scale as a valuable opportunity to improve our solution and accelerate both its market launch and adoption.
Where do you see your startup in one year? And in five years?
In the short term, we aim to make PD-Watch available in Europe, both for screening and for ongoing monitoring in people already affected by Parkinson’s. In five years, we hope to see it widely adopted, bringing real value to patients and clinicians around the world.
Which books, podcasts, or resources do you recommend to other entrepreneurs?
Books like Zero to One offer valuable perspectives on the effort and mindset required to build something from the ground up. In addition to literature, we’ve learned a great deal from our ongoing conversations with mentors, healthcare professionals, patients, and users. These exchanges—though informal—have often provided insights just as meaningful as any written source.
Biomedical Lab is open to connecting with professionals in commercial and regulatory fields. Interested individuals are welcome to reach out at bielle@biomedicallab.it. For more information about the company, visit https://www.biomedicallab.it.